Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome

  • STATUS
    Recruiting
  • End date
    Mar 9, 2024
  • participants needed
    80
  • sponsor
    AbbVie
Send
Updated on 10 July 2022
See if I qualify
myeloid leukemia
ejection fraction
leukemia
azacitidine
blast cells
venetoclax

Summary

Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for participants who are unable to undergo intensive chemotherapy, the current standard of care. This study is to evaluate how safe lemzoparlimab is and how it moves within the body when used along with azacitidine and/or venetoclax in adult participants with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Adverse events and maximum tolerated dose (MTD) of lemzoparlimab will be assessed.

Lemzoparlimab (TJ011133) is being evaluated in combination with azacitidine and venetoclax for the treatment of acute myeloid leukemia (AML) and with azacitidine with/without venetoclax for myelodysplastic syndrome (MDS). Study doctors place the participants in 1 of 5 groups, called treatment arms. Each group receives a different treatment. Adult participants with a diagnosis of AML or MDS will be enrolled. Around 80 participants will be enrolled in the study in approximately 50 sites worldwide.

Participants will receive lemzoparlimab (IV) once weekly (Q1W), venetoclax oral tablets once daily (QD) for 28 days (AML participants) or 14 days (MDS participants) and Azacitidine by SC or IV route QD for 7 days of each 28-day cycle.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests and checking for side effects.

Details
Condition Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Treatment Azacitidine, venetoclax, Lemzoparlimab
Clinical Study IdentifierNCT04912063
SponsorAbbVie
Last Modified on10 July 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Documented confirmation of acute myeloid leukemia (AML) according to the World Health Organization (WHO) criteria, previously untreated [OR]
Documented diagnosis of previously untreated de novo myelodysplastic syndrome (MDS) according to the 2017 WHO classification with presence of < 20% bone marrow blasts per marrow biopsy/aspirate
Participants with documented MDS must meet the following disease activity criteria
Overall revised international prognostic scoring system (IPSS-R) score > 3 (intermediate, high, or very high)
Eastern cooperative oncology group (ECOG) performance status of 0 to 2
Hematopoietic stem cell transplant (HSCT) ineligible, or participant who chooses not to undergo HSCT
Participants with documented AML with adverse cytogenetic and/or molecular risk, and
must be considered ineligible for induction therapy defined by the following
>= 75 years of age; [OR]
>= 18 to 74 years of age with at least one of the following comorbidities: --- Eastern cooperative oncology group (ECOG) performance status of 2 to 3; --- Cardiac history of congestive heart failure requiring treatment or ejection fraction <= 50% or chronic stable angina
Diffusion capacity of lung (DLCO) <= 65% or forced expiratory volume during the first second (FEV1) <= 65%
Creatinine clearance >= 30 mL/min to < 45 mL/min
Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy or the participant declines to receive intensive chemotherapy
Japan Safety Lead-In Phase
Moderate hepatic impairment with total bilirubin > 1.5 to <= 3.0 × upper limit of normal (ULN)
Documented confirmation of AML according to WHO criteria, relapsed or refractory (R/R) disease without other standard of care treatments
Documented diagnosis of MDS according to the 2017 WHO classification with presence of < 20% bone marrow blasts per marrow biopsy/aspirate, with intermediate- and high-risk relapsed/refractory MDS
Documented MDS must meet the following disease activity criteria
ECOG performance status of 0 to 2

Exclusion Criteria

Participants with documented AML with acute promyelocytic leukemia and considered eligible for induction therapy
Participant with documented AML having prior diagnosis of
Participants with documented MDS having prior diagnosis of
Therapy-related MDS
MDS evolving from a pre-existing myeloproliferative neoplasm (MPN)
\-- known active central nervous system involvement with AML
MDS/MPN including chronic myelomonocytic leukemia, atypical chronic myeloid leukemia, juvenile myelomonocytic leukemia and unclassifiable MDS/MPN
History of allogeneic HSCT or solid organ transplantation
History of an active malignancy within the past 2 years prior to Screening, with the exception of
Previous exposure to anti-CD47 therapies
Adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin
Asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy
\-- Adequately treated carcinoma in situ of the cervix uteri or carcinoma in
Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent
situ of the breast
Conditions that could interfere with drug absorption including but not limited to
short bowel syndrome
Japan Safety Lead-In Phase
Documented AML have Acute Promyelocytic Leukemia
Participant with documented AML having prior diagnosis of
\-- Chronic myeloid leukemia with or without BCR-ABL1 translocation and AML
with BCR-ABL1 translocation
Participants with documented MDS having prior diagnosis of
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

myeloid leukemia
ejection fraction
leukemia
azacitidine
blast cells
venetoclax

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note